Insmed shelved Brinsupri as it faced a mid-stage trial failure in hidradenitis suppurativa, a painful chronic skin condition. The company’s decision follows a prior pivot late last year when it dropped a pill candidate in sinus inflammation. The program reset illustrates how quickly companies are cutting development spend when efficacy signals do not land in clinical testing. For dermatology pipelines, the move also highlights how HS remains an area with high attrition and a high bar for differentiation versus existing regimens. Insmed’s update adds to the broader pattern of portfolio reshaping among mid-size biopharma firms as they manage capital intensity and prioritize assets with clearer clinical read-through. While Insmed did not signal immediate replacement candidates in the provided report, the Brinsupri discontinuation narrows near-term options for HS investors tracking pipeline risk and de-risking progress.